Cargando…
Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection
BACKGROUND: In separate phase 2 trials, 120 patients received maribavir for cytomegalovirus (CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for asymptomatic infection (trial 203). Overall, 172 cleared their CMV infection (CMV DNA <200 copies/mL) within 6 weeks....
Autores principales: | Chou, Sunwen, Song, Kening, Wu, Jingyang, Bo, Tien, Crumpacker, Clyde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441206/ https://www.ncbi.nlm.nih.gov/pubmed/32726419 http://dx.doi.org/10.1093/infdis/jiaa462 |
Ejemplares similares
-
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial( )
por: Avery, Robin K, et al.
Publicado: (2021) -
Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009) -
Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
por: Gandhi, Ronak G, et al.
Publicado: (2022) -
Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus
por: Houldcroft, Charlotte J., et al.
Publicado: (2016) -
The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)